HIV remission and treatment control
Clinical research in HIV-1 focuses on post-treatment viral control, immune-based strategies, and maintenance of suppression in people living with HIV. The sponsor supports studies in primary infection, chronic infection, and treatment simplification, with attention to sustained virological success and interruption of standard therapy under controlled conditions.
- Post-treatment HIV control
- Broadly neutralising antibodies
- Antiretroviral therapy
- Two-drug maintenance regimens
Research also includes immune-modulating approaches intended to shape viral persistence and support longer-term remission in treated populations.
Hepatitis B cure-oriented research
The sponsor funds studies in chronic hepatitis B with a strong interest in reducing HBsAg and exploring strategies that may alter the liver immune environment. Its work includes treatment discontinuation concepts and immune stimulation approaches aimed at improving virological outcomes in HBeAg-negative disease.
- Chronic hepatitis B
- HBsAg decline
- NUC discontinuation
- Liver immune modulation
These studies reflect interest in functional cure pathways and immune-based intervention in hepatology.
Vaccine and immunogenicity studies
Research activity also extends to SARS-CoV-2 vaccine evaluation in healthy participants, with attention to booster responses and comparative safety and immunogenicity of candidate vaccines. The sponsor’s portfolio includes adult vaccination studies and experimental medicine approaches in previously vaccinated populations.
- SARS-CoV-2 booster vaccination
- Healthy participants
- Vaccine safety
- Immune response assessment
These trials involve both authorised and investigational vaccine candidates for respiratory viral protection.
Pan-coronavirus vaccine development
The sponsor is involved in development of broader coronavirus vaccine candidates, including pan-coronavirus booster strategies in adults. This area centres on cross-protective immunisation and the evaluation of adjuvanted and non-adjuvanted vaccine formulations.
- Coronavirus vaccine candidates
- Booster immunisation
- Cross-protective immunity
- Adult vaccination
Work in this domain supports clinical investigation of immune breadth against diverse coronavirus strains.
